New animal research being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May), reveals distinct metabolic adjustments to tirzepatide and semaglutide treatment, with ...
PHOENIX -- Use of tirzepatide (Mounjaro, Zepbound) was associated with significantly lower risks of death, hospitalization, and major cardiovascular events compared with semaglutide (Ozempic, Wegovy) ...
Patients with end-stage renal disease or preexisting thyroid disease are more likely to experience either a new thyroid problem or a worsening of their thyroid disease while on tirzepatide.
Tirzepatide, a dual incretin agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has favorable effects on glycemic control and body weight. The effects ...
HOUSTON — The dual GLP-1/GIP receptor agonist tirzepatide showed significantly greater efficacy than the GLP-1 dulaglutide in the treatment of major kidney outcomes in patients with type 2 diabetes ...
Please provide your email address to receive an email when new articles are posted on . The clinical benefits of tirzepatide in patients with HFpEF and obesity were consistent regardless of kidney ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Adults receiving tirzepatide in the SURPASS trials had ...
Tirzepatide's dual mechanism targets GIP and GLP-1, so it provides strong cardiovascular benefits, said Stephen Nicholls, MBBS, PhD, MBA. The dual glucose-dependent insulinotropic polypeptide (GIP) ...
Semaglutide or tirzepatide should be the first line treatment for people living with obesity and most of its complications, according to a new framework for the pharmacological treatment of obesity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results